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Abstract 
The current paper continues our study on the ability of L-arginine to prevent/reduce the 
aggregation of proteins that results from the various stresses during the lyophilisation 
and/or storage of lyophilized protein-based products. The first part of our study, i.e. 
formulation development, was devoted to the rational design and optimization of an L-
arginine containing lyophilized formulation which can resist the natural tendency of L-
arginine to absorb atmosphere moisture. Mannitol and trehalose were chosen among 
other excipients to be included in the protein-based formulation, as mannitol in a 
combination with L-arginine has been shown to reduce moisture sorption while trehalose 
provides a degree of lyoprotection. In the present study, a number of formulations, which 
comprised bovine serum albumin (BSA) with and without L-arginine, and with five 
different ratios of trehalose-to-mannitol (from 30:70 to 80:20) were lyophilised and 
assessed. The internal structures and the moisture sorption/retention of the lyophilized 
formulations were characterised. To study the effect of L-arginine on BSA solid-phase 
stability, the lyophilized powder was exposed to accelerated storage conditions (high 
moisture (75% RH) and temperature (22 or 45 °C)) for up to 24 h. The lyophilized BSA 
formulations were then reconstituted and solution-state protein aggregation assessed by 
turbidimetry at 360 nm and fluorescence spectroscopy using the thioflavin T assay. It 
was demonstrated that L-arginine can be used in protein-based freeze-dried formulations 
to significantly reduce the aggregation of protein during the manufacturing, storage and 
subsequent reconstitution. The results also revealed the importance of a sufficient 
amount of mannitol in the arginine-containing formulations. 
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Since the late twentieth century, different protein-based therapeutics (bio-
pharmaceuticals) and peptide-based products have emerged in the drug market (1–6). 
Today, approximately 20% of all commercial pharmaceuticals are bio-pharmaceuticals 
(7 and references therein) and the global biotherapeutics market is expected to reach 
$386.7 billion by the end of 2019 (8). Monoclonal antibodies represent the majority of 
bio-pharmaceuticals on the market followed by hormones and growth factors (7 and 
references therein). Proteins and polypeptides offer the distinct advantages of specific 
mechanisms of action and are highly potent. However, they also present certain distinct 
challenges which originate from their immunogenicity, high molecular weights and 
instability (aggregation/denaturation) (9–12). 
 
Protein destabilisation/denaturation and aggregation during manufacturing and storage is 
a significant problem in the biopharmaceutical industry as aggregates decrease the 
activity of a protein and hence lower the efficacy of a protein-based drug product 
(4,8,9,13,14). Moreover, certain aberrations (i.e. abnormalities) in protein structure or 
the presence of protein aggregates can trigger immunogenic reactions in the patient. 
Lyophilisation, or freeze-drying, is often used to increase the stability and shelf life of 
bio-pharmaceutical protein-containing drug products (1,3,4). However, freezing and 
dehydration introduce some additional stresses such as cold denaturation, liquid-phase 
separation, freeze concentration, pH change and structure destabilisation due to the loss 
of the protein hydration shell, etc. (1,4,15,16). Stresses that can compromise the protein 
structure and efficacy can occur at many stages in the production of a lyophilised 
product. These include shearing from mixing or shaking, freeze-thawing, drying—as 
well as during temperature and relative humidity fluctuations during storage and 
during/after reconstitution (1,14,17–22). 
 
Various types of excipients (sugars, polyols, amino acids, monovalent electrolytes) are 
used to enhance the physical and chemical stability of peptide and protein 
pharmaceuticals (5,15,23–29). The mechanisms of protein stabilisation by different 
sugars are discussed widely in the literature (for instance, see the recent reviews (30,31). 
Two of the main mechanisms of stabilisation by sugars are (i) water substitution by 
hydrogen bonded sugar molecules at the surface of protein (thermodynamic stabilisation) 
and (ii) vitrification which leads to the suppression of molecular mobility (kinetic 
stabilisation). 
 
Among the 20 naturally occurring amino acids, L-arginine (ArgHCl) has become 
recognised as an excipient which increases the solubility of proteins and suppresses their 
aggregation (24 and references therein, 32–35) and co-aggregation (36) in solution. 
Recent studies have shown that arginine can also improve the solid state stability of 
freeze-dried protein pharmaceuticals (28,37). The stabilisation provided by arginine 
strongly depends on the arginine concentration and the type of counter-ions (36 and 
references therein). 
 
The present paper continues our study (38) on the effect of arginine on protein 
aggregation during the manufacturing process and storage. The ultimate aim of this study 
was to assess the ability of arginine to prevent/reduce protein aggregation caused by the 
various stresses encountered during lyophilisation, storage and/or reconstitution of a 
lyophilized product. However, introducing arginine into a protein-based lyophilized 
product is challenging because of its hygroscopicity that is not considered in some works 
related to freeze-dried formulations containing L-arginine. It is known that the extent of 
protein aggregation in the solid state is related to both the residual water, at the end of 
the process cycle, and to the amount of water absorbed by the protein on storage, and is 
due to the impact of water on the conformational dynamics of the protein molecule 
(39,40). Therefore, the first part (38) of our study—excipient selection (formulation 
development)—was devoted to the rational design and optimization of a formulation that 
can resist or, at least, significantly reduce the moisture uptake by lyophilized samples 
containing L-arginine. 
 
Appropriate excipients (sugars/polyols) were selected according to their ability to (i) 
form elegant cakes and (ii) absorb the least amount of moisture when combined in a 
binary mixture with L-arginine. The study showed that, among several commonly used 
sugars/polyols (i.e. mannitol, trehalose, sucrose, lactose), mannitol was by far the best in 
terms of its ability to resist moisture sorption by the freeze-dried cakes containing 
arginine, even when stored at very harsh conditions. Having selected mannitol as  the best 
moisture protector in combination with arginine, a third excipient (trehalose) was chosen 
as it provides lyoprotection and allows producing acceptable freeze-dried (FD) cakes in 
ternary formulations. 
 
Analysis of a number of quality attributes (i.e. moisture uptake, cake shrinkage, 
mechanical properties, internal structure) of the lyophilized 3-excipient formulations 
(containing L-arginine + mannitol + trehalose) showed that the property dependencies on 
the trehalose content were non-linear (38). Therefore, in the final part of our study, 
reported in this article, several trehalose-to-mannitol ratios were selected for test in the 
protein-containing formulations. Overall, five excipient compositions with different 
trehalose-to-mannitol ratios, with or without L-arginine, were used to prepare the 
protein-based formulations. Lyophilized samples with (Arg+) and without arginine 
(noArg) were studied comparatively. The internal structures and the moisture 
sorption/retention abilities of the lyophilized samples were characterised. Since the main 
emphasis of the present research was on the study of the impact of L-arginine on protein 
stability during manufacturing and storage of lyophilised product, before reconstitution 
cakes were exposed to the stressed storage conditions (increased relative humidity (75%) 
and either room (22 °C) or elevated temperature (45 °C)) which can damage proteins and 
accelerate protein aggregation. The stability test was followed by protein reconstitution 
and measurement of the extent of protein aggregation. 
 
 




Bovine serum albumin (BSA), L-arginine hydrochloride (ArgHCl), trehalose dihydrate, 
D-mannitol and Tris buffer salt (ACS reagent grade) were purchased from Sigma-Aldrich 
Co, UK. Unless otherwise specified, all materials and reagents were of analytical grade 





Stock solutions (10% w/v) of BSA, trehalose, mannitol and L-arginine hydrochloride in 
20 mM Tris-HCl buffer (pH 7.2) were prepared immediately prior to freeze-drying. 
Samples were mixed accordingly and freeze-dried using Heto FD8 freeze-drier 
(Germany) in transparent glass vials (one vial contained 2 ml of solution such that the 
total weight of solids was 0.2 g per vial) using the freeze-drying cycle described in (38). 
To reduce radiation effects (41), vials were loaded in a close hexagonal packing profile 
in the centre of a shelf. Product temperature was monitored using a thin wire 
thermocouple. At the end of the freeze-drying cycle, the vials were stoppered under 
vacuum and crimped with aluminium seals. Samples were stored in a desiccator in a dry 
cold place. 
 
Through-Vial Impedance Spectroscopy 
Aliquots (2 or 3 ml) of freshly prepared 10 wt% BSA solution with and without arginine 
were added to the specially designed impedance measurement vials connected to the 
data-acquisition system (42), placed on a freeze-dryer shelf and exposed to the same 
freeze-drying cycle used to prepare FD samples. The impedance measurements were 
performed over a frequency range of 10–10
6
 Hz with a scan interval of 3 min as 
described previously (43). 
 
Moisture Sorption 
Freeze-dried samples were placed in aluminium foil boats and incubated in a desiccator 
at 75% relative humidity (RH) at either 22 or 45 °C. Incubation of the lyophilized 
powders at constant RH was achieved by vapour equilibration in desiccators over NaCl 
saturated solution. Weight of the samples over time was measured gravimetrically and 
moisture uptake was calculated as 
where Wm and Wd are the weight of moist and dry powder, correspondently. 
 
Thermogravimetric Analysis 
A Perkin-Elmer Pyris 1 thermogravimetric analyser (USA) was used to record the water 
evaporation profiles and to assess the moisture content in freeze-dried powder samples. 
Five to fifteen milligrams of powder was placed into a thermogravimetric analysis 
(TGA) aluminium pan; the pan was sealed and a hole was made using a needle. Samples 
were heated from 25 to 300 °C at a rate of 10 °C/min under nitrogen atmosphere and the 
decrease in sample weight was monitored. Onset and endpoint temperatures were 
calculated using Pyrus software. 
 
Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) measurements were carried out using a Perkin -
Elmer Jade DSC (USA). Between 5 and 10 mg of the FD powder was placed into an 
aluminium DSC pan and crimped with vented lid. Samples were heated either (i) from 0 
to 180 °C at 1 °C/min; or (ii) from − 20 to 300 °C at 10 °C/min. Melting temperatures 
and the enthalpy of melting were calculated using the Pyris software. 
 
Scanning Electron Microscopy 
The internal structures of the BSA-containing freeze-dried cakes at different 
magnifications (× 250, × 500, × 1000, × 5000) were visualised using a Carl Zeiss EVO 
HD scanning electron microscope (UK). Powder samples were mounted on 12.5 
scanning electron microscopy (SEM) pin metal stubs using 12 mm carbon tabs (Agar 
scientific). 
 
Protein Reconstitution and Aggregation Assay 
Prior to reconstitution, the freeze-dried cakes were incubated for 24 h at 75% RH and 22 
or 45 °C. Proteins were reconstituted by adding double distilled water to the FD cakes at 
4 °C, until complete dissolution of the powder was achieved. The protein concentration 
was measured using a UV-Vis spectrophotometer with a 1-cm path-length quartz cuvette. 
The percent solution extinction coefficient was taken as 6.67 E1% for BSA at 280 nm 
(44). Protein concentration was adjusted to keep it constant in solutions with and without 
arginine. The UV-Vis spectra of the reconstituted proteins were recorded in the range 
240–400 nm and the A260/A280 ratios calculated. 
Reconstituted protein solutions were incubated at room temperature (22 °C) and the 
formation of aggregates was assessed by measuring the apparent absorbance at 360 nm 
caused by increased turbidity (turbidimetry assay), using a Thermo-Scientific UV-Vis 
Evolution 60S spectrophotometer. Before the optical density measurements, the protein 
solution was mixed in order to re-suspend any aggregates that may have precipitated on 
standing. The formation of aggregates was also confirmed by light microscopy.  
 
Fluorescence Spectroscopy (ThT Assay) 
ThT stock solution (1 mM) was prepared using double-distilled water and filtered using 
a 0.2 μm syringe filter. The stock solution was stored at 4 °C for no longer than 1 month. 
All samples containing ThT were kept in the dark to minimise photobleaching. In a 
typical experiment, 300 μl of reconstituted protein solution was mixed with 1.7  ml of 
Tris-buffer followed by the addition of a small aliquot of ThT stock solution to the 
working reaction, immediately before the measurement. The final ThT concentration in 
solution was 10 μM. The pHs of the buffer and the protein solutions were kept at 7.2 as 
both acidic and basic pHs are known to decrease the ThT fluorescence emission (45). 
Fluorescence measurements were carried out using a LS55 spectrofluorometer (Perkin-
Elmer, UK) in 1-cm quartz cuvettes containing 2 ml of unstirred solution. The 
temperature inside the cuvette was maintained at 25 °C by a thermostatic cell holder. 
ThT emission spectra were recorded in 0.5 nm increments by exciting the sample at 
445 nm and collecting the emission between 455 and 650 nm; the excitation and 
emission slit widths were set at 2.5 and 5 nm, respectively. 
 
RESULTS AND DISCUSSION 
 
Freeze-Dried Formulations Containing BSA, Mannitol, Trehalose and 
L-Arginine 
Five formulations containing protein (BSA, 50 wt%), D-mannitol, trehalose and L-
arginine (10 wt%) with different trehalose:mannitol ratios were prepared (Table I). Five 
control formulations contained the same trehalose:mannitol ratios but without L-arginine. 
The ratios between protein, mannitol and trehalose were kept the same for arginine-
containing and arginine-free samples. Hereinafter, the formulations containing L-arginine 
will be named as Arg+ and those without arginine—noArg. After freeze-drying, all 








Compositions of the Freeze-Dried Formulations Containing Protein (BSA), Mannitol, 












T12 30:70 50% 28 12 10 
T16 40:60 50% 24 16 10 
T20 50:50 50% 20 20 10 
T24 60:40 50% 16 24 10 
T32 80:20 50% 8 32 10 
 
 
Arginine Effect on Freeze-Drying of the Protein Formulation 
Through-vial impedance spectroscopy (42,43) was used to monitor the effect of arginine 
on the rate of primary drying of the protein-based formulations. This technique is based 
on the measurements of impedance (or electric capacitance) over a wide frequency range 
using an electrode system affixed to the outside of a standard 10-ml glass lyophilisation 
vial filled with the BSA solution to be freeze-dried (41). During freezing and drying 
stages the temperature, physical state and composition of the sample are changing 
dramatically due to the aqueous phase freezing and the sublimation of ice, causing 
significant changes in impedance (42). 
 
Figure 1a presents 3D plots of dielectric loss as a function of time and frequency for two 
10 wt% protein solutions without and with Arg (55% BSA, 22.5% trehalose, 22.5% 
mannitol and 50% BSA, 20% trehalose, 20% mannitol, 10% arginine). The proportion 
between protein, trehalose and mannitol was kept constant in both samples. The 
capacitance values C″ of the relaxation peaks calculated using a bespoke peak funding 
algorithm (42) are presented in Fig. 1b. The capacitance is proportional to the dielectric 
permittivity that differs significantly for ice (> 90) and for dry excipients (< 5) (46). As 
the height of the ice layer decreases due to water sublimation, the dielectric loss peak 
decreases over time (Fig. 1b). The initial rate of C″ decrease can be associated directly 
with the rate of water sublimation. Once the ice layer reaches the bottom edge of the 
electrode then the magnitude of the ice peak (C″) decreases to zero and hence the time to 





Monitoring of freeze-drying process using TVIS system. a 3D dielectric loss spectra 
(imaginary part of capacitance, C″ vs. time and frequency) monitored during the freeze-
drying process of T20 samples including 10 wt% L-arginine (left) and without L-arginine 
(right). b The magnitude of the spectrum peak of the imaginary part of dielectric 
capacitance C″ vs. time for T20 samples with (1, 4) and without L-arginine (2, 3). Total 
volume of liquid in a vial: 2 ml (3, 4) and 3 ml (1, 2). Insert: end set of the primary 
drying time for T20 samples with/without arginine 
 
 
As expected, the time when C″PEAK approaches zero for the 3 ml sample occurred 8–10 h 
later than for the 2 ml sample. Arg presence had no significant effect on the end point 
time for the 2-ml sample; 3-ml sample containing Arg dried ca. 4 h faster than the 
sample without arginine. This result coincide with our previous finding for the protein-
free two- and three-component systems containing mannitol and trehalose (38), where 
noArg samples dried slower than Arg+. The arginine effect on the ice sublimation time 
was more pronounced in the case of protein-free samples described in our Part I paper 
(38) as they contained higher percentage of arginine (20 wt%). 
 
In (38), we have suggested that the increased sublimation rate for the arginine-containing 
formulation is probably related to the facilitated diffusion of water in this system. 
Formation of a surface layer on the top of a sample during freezing process can also 
contribute to the slower rate of sublimation in the case of noArg formulations. 
 
Effect of Arginine on the Internal Structure of Freeze-Dried Products 
SEM images (Fig. 2) illustrating the internal structures of lyophilized powders reveal 
that dry BSA-sugar samples, both with and without L-arginine, resemble hexagonal 
honey-comb structures typical for many freeze-dried products. The presence of arginine 
in the formulation does not have a significant impact on the type of the structure and on 
the size of hexagonal cells. However, there is a small tendency towards decrease in the 
pore sizes and the wall thicknesses in the FD samples containing arginine (in comparison 
to the arginine-free FD samples). As arginine comprises only 10 wt% of a sample, it is 






SEM images (× 500) of lyophilized samples (T12, T20 and T32, see Table I) with (Arg+) 
and without (noArg) L-arginine (10 wt%) 
 
Moisture Uptake by FD Formulations Containing BSA With/Without L-
Arginine 
Freeze-dried cakes were subjected to a humidified environment in order to assess their 
moisture sorption properties. Cakes were incubated at 75% RH at room temperature 
(22 °C) during 24 h and the weight gain over time was monitored. The total moisture 
uptake after 24 h was assessed gravimetrically (TGA and analytical balances).  
 
Kinetic measurements of the moisture sorption show that the weight of FD cakes 
increases with time (Fig. 3a). For all samples, the first hour of moisture treatment had 
the biggest impact on the total amount of moisture uptake with between 55 and 65% of 
the total moisture being accumulated after 1 h of incubation at high relative humidity. In 
addition, during the first hour of moisture treatment no significant difference was 
observed between the moisture accumulation by the noArg and the Arg + FD 
formulations (Fig. 3a). Figure 3b shows that the total moisture content in the FD cakes 
after moisture treatment increases when the trehalose content increases (and, 
consequently, mannitol content decreases). For all trehalose-to-mannitol ratios, those FD 
formulations containing arginine (Arg+) accumulated more moisture than those without 




Moisture uptake by FD formulations containing BSA, trehalose, mannitol with or 
without L-arginine during moisture treatment at 75% RH and room temperature. a 
Kinetics of moisture sorption by lyophilised T16 formulations without (noArg) and with 
(Arg+) L-arginine. b Total moisture uptake by formulations after 24 h of incubation at 
75% RH. Formulation compositions are presented in Table I 
 
The presence of arginine in the formulation also changed the moisture release profiles. 
Figure 4 shows the TGA thermograms illustrating the weight loss by moisture-treated 
FD cakes comprising albumin (50%), trehalose and mannitol with/without Arg. A typical 
TGA thermogram shows two steps, where the first step is mainly the result of the weight 
loss due to moisture evaporation and the second step is due to material decomposition at 
higher temperatures. For the cakes containing no Arg (Fig. 4a, curve “1”), the moisture 
evaporation profiles are almost independent of the trehalose and mannitol content. In the 
case of Arg-containing formulations, the TGA profiles strongly depend on trehalose-to-
mannitol ratio. Low-to-average trehalose content formulations containing Arg (T12-T24, 
see Table I) show only minor differences from the non-Arg formulations (Fig. 4a, top). 
The presence of Arg in formulations with high trehalose/low mannitol content (T32, Fig. 
4a, bottom left) leads to a strong alteration of the TGA profiles, in that there is a 
significant increase in the end temperature of the moisture evaporation while the onset 
temperature remains almost unchanged. This results in a strong increase in the 
temperature interval (ΔT) of the moisture evaporation (Fig. 4a, bottom right) from the 





TGA study of moisture release by FD formulations containing BSA, trehalose, mannitol 
with/without L-arginine. Prior to TGA, all FD formulations were moisture-treated by 
incubating at 75% RH, 24 h, 22 °C (a) or 45 °C (b). a, b Top and bottom left—TGA 
thermograms recorded from 25 to 300 °C at 10 °C/min illustrating the weight loss by 
moisture-treated formulations T12, T24 and T32 (see Table I). a, b Bottom right—
dependencies of the temperature interval of moisture release ΔT (where ΔT = Tendset – 
Tonset) on the trehalose content in formulation 
 
Moisture treatment (75% RH) at elevated temperature (45 °C) for 24 h resulted in more 
pronounced differences between the noArg and the Arg+ formulations at lower trehalose 
concentrations. As Fig. 4b shows, both T24 and T32 Arg+ formulations possess altered 
TGA moisture evaporation profiles in comparison to noArg formulations. Moreover, 
elevated temperature in combination with increased moisture resulted in a colour change 
from white to light brownish in the case of Arg+ formulations.  
 
Overall, the moisture treatment results show that the presence of arginine in BSA-based 
FD formulations increases the moisture uptake by approximately 10–15% after 24 h of 
incubation at 75% RH. Arginine also makes the process of water evaporation more 
gradual by increasing the endpoint temperature. At the same time, a high content of 
mannitol in a formulation diminishes/compensates the effect of Arg on moisture 
sorption. 
 
Thermal Stability of Freeze-Dried BSA Formulations With/Without L-Arginine 
DSC thermograms (Fig. 5a) of formulations comprising BSA (50 wt%), trehalose 
(24 wt%), mannitol (16 wt%) with/without Arg (10 wt%) after moisture treatment (75% 
RH, 24 h, room temperature) were recorded to assess the impact of arginine on the 
thermal stability of the protein. Both thermograms have a thermal peak around 66–68 °C 
which corresponds to the BSA melting temperature (47). The presence of Arg does not 
shift the peak temperature. This result is in accordance with the known fact that arginine, 
being an aggregation suppressor, does not enhance the protein thermal stability (48,49). 
Arginine also has a minimal effect on the enthalpy of the endothermic transition, ΔH, 
equal to 279 ± 20 J/g (since the samples were moisturised, the water evaporation might 





DSC thermograms of FD formulations containing BSA, trehalose, mannitol with/without  
L-arginine. a Thermograms for formulation T24 (see Table I) recorded from 0 to 180 °C 
at 1 °C/min. Samples were pre-treated at 75% RH, room temperature, during 24 h prior 
to measurements. b Thermograms recorded from 0 to 300 °C at 10 °C/min for samples: 
1—T12 Arg+; 2—T32 Arg+; 3—T12 noArg; 4—T32 noArg L-arginine 
 
DSC thermograms for BSA-containing freeze-dried noArg/Arg+ formulations with 
different trehalose-to-mannitol ratios recorded in the wide range of the temperatures (at 
10 °C/min) are shown in Fig. 5b. The endothermal peak in the 140–150 °C region (Fig. 
5b) is associated with melting of mannitol (38,50). The presence of a melting peak 
confirms that mannitol is, at least partially, in the crystalline state in the freeze-dried 
samples containing BSA. It is known that D-mannitol has three common polymorphic 
forms and (partial) crystallisation of mannitol during the freeze-drying process can 
produce different anhydrous polymorphs (α, β and δ) (51) and a hemihydrate form 
(52,53). Three polymorphs do not undergo transformations under mechanical stress or 
long periods of storage (52 and references therein). The α and β polymorphs have very 
similar crystal structures and nearly identical physical properties including melting 
points (52). As is seen in Fig. 5b, in noArg protein-containing freeze-dried samples, 
mannitol predominantly forms one polymorph if a formulation contains low amount of 
mannitol and high amount of trehalose (T32 formulation in Fig. 5b) and forms two 
polymorphs if the amount of mannitol is increased (T12 in Fig. 5b). 
 
Low melting enthalpy values (11 ± 5 J/g) reflect the fact that only a small part of 
mannitol is in crystalline form in the protein-containing noArg formulations. Perhaps, 
the overall low percentage of mannitol in the samples (from 8 wt% in T32 to 28 wt% in 
T12, Table I) makes it difficult for mannitol to crystallise. Besides, the presence of a 
high amount of a protein (BSA) in formulations can potentially delay and reduce the 
amount of mannitol crystallisation as it has been showed recently (54). 
 
The presence of arginine had no significant effect on the amount of crystalline mannitol 
and its polymorphs in the protein formulations with low amount of mannitol (T32 
sample, Fig. 5b). However, when the amount of mannitol increased (T12 sample), the 
presence of arginine resulted in the mannitol conversion into a single polymorph form 
(Fig. 5b). At the same time, the total amount of crystalline mannitol in the sample 
increased almost four times as revealed by increased value of the melting enthalpy (ΔH 
values were ~15 J/g for noArg T12 sample and ~58 J/g for Arg+ T12 sample). Thus, the 
presence of L-arginine increases mannitol crystallisation in protein-containing 
formulation, however, only if the mannitol content is higher than the trehalose content. It 
was shown recently that in the mixture of mannitol and trehalose, the crystallisation 
behaviour of both solutes, after freeze-drying, depends on the mannitol to trehalose ratio 
(R): when R ≥ 1, the extent of mannitol crystallisation was directly proportional to the 
value of R, when R < 1, trehalose completely suppresses mannitol crystallisation (55). 
Our results also show that the amount of crystalline mannitol is lower in formulations 
with mannitol-to-trehalose ratios < 1. Thus, it cannot be excluded that high trehalose 
and/or BSA content (but not arginine alone) determine the low amount of crystalline 
mannitol in the formulations. 
It is of interest to note that the effect of arginine on the polymorph forms of crystalline 
mannitol was very similar in the protein-free formulations containing mannitol, trehalose 
and L-arginine, as reported in our first paper (38). On decreasing the mannitol content 
(and, consequently, increasing the trehalose content with fixed Arg concentration), an 
endothermic double peak was observed close to 150 °C which is consistent with the 
peaks from the β and δ forms of mannitol being shifted towards lower temperatures and 
transformed into a broad single asymmetric peak with a shoulder. This result shows that 
the effect of arginine on the mannitol crystallinity in freeze-dried products is not 
significantly altered by a presence of even a large amount of BSA in a sample.  
 
The endothermic peak close to 220 °C (Fig. 5b) can be ascribed to trehalose melting, 
after first devitrification during DSC run. Melting of freeze-dried trehalose at these 
temperatures was observed previously (for example, see (56,57)). The presence of 
arginine does not alter this peak significantly. It is often expected that after freeze-
drying, trehalose is in amorphous state and undergoes a glass transition in the 
temperature interval 80–120 °C (according to different literature data and depending on 
the sample content, method of preparation, moisture, etc.; for instance, authors of (57) 
observed trehalose glass transition at 117–118 °C). In the current study, a number of 
overlapping peaks in this temperature interval makes it impossible to observe a trehalose 
glass transition. 
 
In the presence of L-arginine, the endothermic peak around 220 °C (Fig. 5b) becomes 
broader, perhaps, due to the arginine contribution. It was shown previously that, unlike 
most amino acids (e.g. glycine, alanine, valine), arginine is at least partially amorphous 
after freeze-drying (58,59); crystallisation could be significantly or completely supressed 
in the presence of HCl when the amino acid salt is formed (see review (37) and 
references therein). It is possible that in our four-component system, L-arginine is, at 
least partially, in a crystalline form. 
 
The presence of the decomposition peak (60) at high temperatures (> ~280 °C) on the 
DSC thermograms of Arg+ samples evidences that sample degradation occurs at these 
temperatures (Fig. 5b). The thermal decomposition was stronger in the presence of Arg+. 
Comparison of the Arg-containing samples shows that the decomposition peak was more 
expressed and shifted towards lower temperatures in the case of the formulations 
containing more trehalose than mannitol. This result is in accordance with our finding 
(described below) that the presence of arginine in formulations with lower levels of 
mannitol facilitates the aggregation of protein at high temperatures.  
 
Reconstitution of FD Formulations Containing BSA With and Without L-Arginine 
To enhance the stresses caused by sample storage and to accelerate protein 
denaturation/aggregation, freeze-dried cakes were pre-incubated for 24 h at 75% RH and 
either 22 or 45 °C. After incubation under these stressed storage conditions, the protein 
samples were reconstituted by adding double-distilled water followed by gentle agitation 
to ensure complete dissolution. UV-Vis spectra of the freshly reconstituted albumin 
samples followed the pattern of a typical native protein spectrum. Control experiments 
showed that immediately after reconstitution, and during the first hour following 
reconstitution, the optical densities at 360 nm of all solutions were very low (< 0.01) 
with no signs of protein aggregation. 
 
Aggregation of the Reconstituted BSA in Solution 
After moisture treatment and reconstitution, the samples were kept at room temperature 
and BSA aggregation in solution was assessed by turbidimetric assay at 360 nm as a 
function of time. Generally, native proteins show no absorbance at wavelengths greater 
than 310 nm. However, when protein aggregates are formed, the optical density at 
360 nm (OD360) increases due to light scattering by the aggregates.  
 
Figure 6a shows the typical time dependencies of optical density at 360 nm for 
reconstituted protein solutions with/without arginine for different trehalose-to-mannitol 
ratios in formulations (Treh:Man 30:70, 40:60, 50:50, 60:40, 80:20). Before 
reconstitution, the samples were moisture treated for 24 h at 75% RH and room 
temperature. For all samples, the optical density at 360 nm (OD360) increases with time 
due to formation of the protein aggregates. The appearance of aggregates was also 
confirmed by light microscopy. The aggregation ratios between noArg and Arg+ samples 
are summarised in Fig. 6b (the aggregation ratios were calculated as ratios between 
OD360 for a Arg+ sample to OD360 for a noArg sample with the same trehalose-to-
mannitol content after 14 days of storage). The data shows that for all five formulations 
containing different trehalose-to-mannitol contents, the degree of protein aggregation is 
2–2.5 times lower in the presence of L-arginine. Besides, the aggregation kinetic curves 
in Fig. 6a show a lag-period during which no aggregation was detected. For all five 
samples examined, the lag-periods are longer in the case of Arg+ sample. Overall, the 
results show that in the case of FD formulations pre-moisturised at room temperature, 





Aggregation of reconstituted protein in solution. a Dependencies of optical density at 
360 nm over time for reconstituted BSA in Tris-buffered solutions with/without l-
arginine. Prior to protein reconstitution FD formulations were pre-incubated at 75% RH 
and 45 °C for 24 h. Formulation compositions (T12, T20, T24 and T32) are given in 
Table I. b The aggregation ratios between noArg and Arg + formulations, where 
OD360(noArg) and OD360(Arg+) are optical densities at 360 nm of the BSA-containing 
formulations without and with l-arginine. Reconstituted protein solutions were incubated 
at room temperature for 14 days before the final level of protein aggregation was taken 
 
 
The presence of protein aggregates in the reconstituted samples was confirmed by 
fluorescence spectroscopy using Thioflavin T (ThT) assay. ThT, a fluorescent dye, binds 
to protein aggregates but not to protein monomer and upon binding displays an enhanced 
fluorescence emission and a characteristic red shift of the emission maximum (61). 
Typical fluorescence emission spectra of ThT alone and in the presence of native protein 
(BSA) in solution are shown in Fig. 7 (curves 1 and 2, 3). The intensity of the 
fluorescence emission of ThT is very low when no protein aggregates are present in 
solution. In the presence of protein aggregates, the emission intensity increases 
remarkably (Fig. 7, curves 4 and 5). ThT fluorescence emission is higher in the case of 
noArg (curve 5) than Arg+ samples (curve 4) indicating higher level of protein 
aggregation in the noArg formulation. The increase in the intensity of ThT emission 
correlates with increase in optical density at 360 nm. Thus, the ThT assay results confirm 
that the presence of L-arginine in a formulation decreases the level of protein 




Steady-state fluorescence emission spectra of ThT: (1)—alone in Tris-HCl buffer; (2)—
in the presence of freshly prepared BSA; (3)—in the presence of freshly reconstituted 
T24 formulation; (4), (5)—in the presence of T24 Arg+ (4) and T24 noArg (5) samples 
incubated during 7 days at room temperature after reconstitution. All samples were 
prepared in 20 mM Tris-HCl buffer (pH 7.2). ThT aliquot from stock solution (1 mM) 
was added to the working reaction immediately before the experiment 
 
 
In the case of FD formulations pre-incubated at elevated temperature (45 °C) and high 
relative humidity (75%) prior to reconstitution, no significant difference between BSA 
aggregation in the presence or absence of L-arginine in the formulations was found for 
four (T12, T16, T20 and T24 samples) out of five formulations studied (Fig.  8). In the 
case of the T32 formulation with the highest trehalose content (80:20 trehalose-to-
mannitol ratio), the degree of protein aggregation was significantly higher in the 
presence of L-arginine (Fig. 8, bottom right). The lag-periods for T32 formulations pre-




Dependencies of optical density at 360 nm over time for reconstituted BSA in Tris-
buffered solutions with/without L-arginine. Prior to protein reconstitution, FD 
formulations were pre-incubated at 75% RH and 45 °C for 24 h. Formulation 
compositions (T12, T20, T24 and T32) are given in Table I 
 
Moisture treatment at elevated temperature, as we showed earlier, also caused significant 
alteration in the TGA moisture release profiles (Fig. 4b) and a change in the colour of 
the powder from white to light brown. This evidences significantly stronger changes in 
the state of protein as a result of pre-treatment with harsher conditions (moisture in 
combination with elevated temperature). In the latter case, hygroscopic L-arginine causes 
more damage to the protein during pre-incubation and is unable to reduce protein 
aggregation (Fig. 8). Therefore, it can be concluded that the presence of L-arginine does 
not always reduce the extent of protein aggregation and under certain conditions arginine 
causes no effect or even increases aggregation. To prevent from this,  high mannitol 
content in product is required. 
 
L-Arginine is the most hydrophilic of the protein-building amino acids, which is able to 
form up to seven hydrogen bonds per molecule (37 and references therein). Being 
introduced into a lyophilized formulation, L-arginine somehow increases the moisture 
uptake by the FD powder thus raising the stress on a protein. At the same time, the 
arginine’s ability to form hydrogen bonds is, perhaps, critical for L-arginine-induced 
protein stabilisation and protein aggregation suppression: according to the water 
replacement theory of protein thermodynamic stabilisation during lyophilisation, the 
stabiliser molecules replace water molecules by hydrogen bonding to the protein. One 
can suggest that the balance between these two effects (as well as the presence of other 
excipients that can diminish the moisture attraction by arginine, in our case mannitol) 
defines the final impact of L-arginine on the protein aggregation. 
 
The results obtained also illustrate the importance of moisture-resistant excipients (i.e. 
mannitol) which can be combined with L-arginine in order to develop a successful 
protein-based pharmaceutical. Formulations containing relatively large amount of 
trehalose (~30–40 wt%) and small amount of mannitol (with mannitol-to-trehalose ratios 
below 1) were shown to be unable to reduce protein aggregation when exposed to high 
humidity and elevated temperatures, during pre-reconstitution storage. Large amounts of 
trehalose in formulations also resulted in the inhibition of mannitol crystallisation after 
freeze-drying and a decrease in the protein degradation temperature. However, it should 
be noted that in the last experiment (Fig. 8, T80 formulation (bottom right)), the 
lyophilized formulations were treated with the extremely severe conditions (a 
combination of high temperature and high humidity) which are very unlikely to be 
encountered in normal storage conditions. Under less harsh conditions, arginine has been 
found to be able to protect proteins in the dried state and to reduce the protein 
aggregation after reconstitution. 
In the present work, a relatively wide range of trehalose concentrations were assessed; in 
future work, the trehalose concentration can be further adjusted with a particular protein 
in mind as trehalose may affect the activity of the protein-based drugs. For instance, the 
recovered activity of phosphofructokinase after freeze-drying was shown to be 
dependent on the trehalose concentration (62). 
 
CONCLUSION 
The current study has demonstrated that L-arginine included in freeze-dried formulations 
leads to a significant decrease in the BSA aggregation. The presence of L-arginine in 
freeze-dried BSA-containing cakes does not compromise the cake physical appearance. 
High hygroscopicity of L-arginine can be significantly compensated by introducing 
mannitol into a protein formulation, as mannitol in a combination with L-arginine can 
strongly resist the moisture sorption. 
 
Trehalose was introduced into the final formulation as a lyoprotectant. As a non-
reducing sugar, trehalose (as well as mannitol) does not react with amino acids or 
proteins in the Maillard reaction and can be safely used in protein-based formulations. 
Formulations containing relatively large amount of trehalose (~30–40 wt%) were shown 
to be unable to reduce protein aggregation when exposed to high humidity and 
temperature during pre-reconstitution storage. Therefore, to develop a successful protein 
formulation containing L-arginine, the trehalose concentration needs to be reduced while 
mannitol concentration is increased, and keeping the mannitol-to-trehalose ratio above 1. 
 
The results obtained in the present study enable the rational design and development of 
the future formulations suitable to protect protein-based pharmaceutics in solid state 
during the manufacturing and storage. 
 
Acknowledgements 
The authors would like to thank Rachel Armitage (De Montfort University) for help with 





1. Carpenter JF, Chang BS, Garzon-Rodriguez W, Randolph TW. Rational design of 
stable lyophilized protein formulations: theory and practice. Pharm Biotechnol. 
2002;13:109–33. 
2. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein 
pharmaceuticals: an update. Pharm Res. 2010;27:544–75. 
3. Izutsu K. Stabilization of therapeutic proteins in aqueous solutions and freeze-dried 
solids: an overview. Methods Mol Biol. 2014;1129:435–41. 
4. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J 
Pharm. 2000;203:1–60. 
5. Remmele RL, Krishnan S, Callahan WJ. Development of stable lyophilized protein 
drug products. Curr Pharm Biotechnol. 2012;13:471–96. 
6. Hansen LJJ, Daoussi R, Vervaet C, Remon JP, De Beer TRM. Freeze-drying of live 
virus vaccines: a review. Vaccine. 2015;33:5507–19. 
7. Lakowitz A, Godard T, Biedendieck R, Krull R. Mini review: recombinant production 
of tailored bio-pharmaceuticals in different Bacillus strains and future perspectives. Eur 
J Pharm Biopharm. 2017;126:27–39. https://doi.org/10.1016/j.ejpb.2017.06.008.  
8. Biotechnology. BCC Research. Feb, 2015. Biologic therapeutic drugs: technologies 
and global markets. Report Code: BIO079C. 
9. Arakawa T, Prestrelski SJ, Kenney WC, Carpenter JF. Factors affecting short-term 
and long-term stabilities of proteins. Adv Drug Deliv Rev. 2001;46:307–26. 
10. Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering 
biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 
2014;13:655–72. 
11. Cromwell ME, Hilario E, Jacobson F. Protein aggregation and bioprocessing. AAPS 
J. 2006;8:E572–9. 
12. Hjorth CF, Norrman M, Wahlund PO, Benie AJ, Petersen BO, Jessen CM, et al. 
Structure, aggregation, and activity of a covalent insulin dimer formed during storage of 
neutral formulation of human insulin. J Pharm Sci. 2016;105:1376–86. 
13. Roberts CJ. Protein aggregation and its impact on product quality. Curr Opin 
Biotechnol. 2014;30:211–7. 
14. Raut AS, Kalonia DS. Pharmaceutical perspective on opalescence and liquid-liquid 
phase separation in protein solutions. Mol Pharm. 2016;13:1431–44. 
15. Carpenter JF, Izutsu K, Randolph TW. Freezing- and drying-induced perturbations of 
protein structure and mechanisms of protein protection by stabilizing additives. In: Rey 
L, May JC, editors. Freeze Drying/Lyophilization of Pharmaceuticals and Biological 
Products. New York: Marcel Dekker, Inc.; 2010. p. 167–97. 
16. Pikal MJ. Mechanisms of protein stabilization during freeze-drying and storage: the 
relative importance of thermodynamic stabilization and glassy state relaxation dynamics. 
In: Ray L, May JC, editors. Freeze drying/Lyophilization of pharmaceutical and 
biological products. New York: Informa Healthcare; 2004. p. 63–108. 
17. Bummer PM, Koppenol S. Chemical and physical considerations in protein and 
peptide stability. In: McNally EJ, editor. Drugs and the pharmaceutical sciences, protein 
formulation and delivery. New York: Marcel Dekker; 2000. p. 15–8. 
18. Pikal-Cleland KA, Rodríguez-Hornedo N, Amidon GL, Carpenter JF. Protein 
denaturation during freezing and thawing in phosphate buffer systems: monomeric and 
tetrameric beta-galactosidase. Arch Biochem Biophys. 2000;384:398–406. 
19. Cao E, Chen Y, Cui Z, Foster PR. Effect of freezing and thawing rates on 
denaturation of proteins in aqueous solutions. Biotechnol Bioeng. 2003;82:684–90. 
20. Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of 
stresses and mechanisms of protein stabilization. Pharm Dev Technol. 2007;12(5):505–
23. 
21. Snell JR, Zhou C, Carpenter JF, Randolph TW. Particle formation and aggregat ion of 
a therapeutic protein in nanobubble suspensions. J Pharm Sci. 2016;105:3057–63. 
22. Roy S, Henderson I, Nayar R, Randolph TW, Carpenter JF. Effect of pH on stability 
of recombinant botulinum serotype a vaccine in aqueous solution and during storage of 
freeze-dried formulations. J Pharm Sci. 2008;97:5132–46. 
23. Jorgensen L, Hostrup S, Moeller EH, Grohganz H. Recent trends in stabilising 
peptides and proteins in pharmaceutical formulation—considerations in the choice of 
excipients. Expert Opin Drug Deliv. 2009;6:1219–30. 
24. Ohtake S, Kita Y, Arakawa T. Interactions of formulation excipients with proteins in 
solution and in the dried state. Adv Drug Deliv Rev. 2011;63:1053–73. 
25. Chang LL, Pikal MJ. Mechanisms of protein stabilization in the solid state. J Phar 
Sci. 2009;98:2886–908. 
26. Forney-Stevens KM, Bogner RH, Pikal MJ. Addition of amino acids to further 
stabilize lyophilized sucrose-based protein formulations: I. Screening of 15 amino acids 
in two model proteins. J Pharm Sci. 2016;105:697–704. 
27. Goshima H, Forney-Stevens KM, Liu M, Qian KK, Tyagi M, Cicerone MT, et al. 
Addition of monovalent electrolytes to improve storage stability of freeze-dried protein 
formulations. J Pharm Sci. 2016;105:530–41. 
28. Stärtzel P, Gieseler H, Gieseler M, Abdul-Fattah AM, Adler M, Mahler HC, et al. 
Freeze drying of L-arginine/sucrose-based protein formulations, part I: influence of 
formulation and arginine counter ion on the critical formulation temperature, product 
performance and protein stability. J Pharm Sci. 2015;104(7):2345–58. 
29. Stärtzel P. Arginine as an excipient for protein freeze-drying: A mini review. J Pharm 
Sci. 2018; 107(4): 960-7. 
30. Mensink MA, Frijlink HW, van der Voort Maarschalk K, Hinrichs WL. How sugars 
protect proteins in the solid state and during drying (review): mechanisms of 
stabilization in relation to stress conditions. Eur J Pharm Biopharm. 2017;114:288–95. 
31. Cicerone MT, Pikal MJ, Qian KK. Stabilization of proteins in solid form. Adv Drug 
Deliv Rev. 2015;93:14–24. 
32. Lange C, Rudolph R. Suppression of protein aggregation by L-arginine. Curr Pharm 
Biotechnol. 2009;10:408–14. 
33. Shukla D, Trout BL. Interaction of arginine with proteins and the mechanism by 
which it inhibits aggregation. J Phys Chem B. 2010;114:13426–38. 
34. Arakawa T, Ejima D, Tsumoto K, Obeyama N, Tanaka Y, Kita Y, et al. Suppression 
of protein interactions by arginine: a proposed mechanism of the arginine effects. 
Biophys Chem. 2007;127:1–8. 
35. Tsumoto K, Ejima D, Kita Y, Arakawa T. Review: why is arginine effective in 
suppressing aggregation? Protein Pept Lett. 2005;12:613–9. 
36. Oki S, Iwashita K, Kimura M, Kano H, Shiraki K. Mechanism of co-aggregation in a 
protein mixture with small additives. Int J Biol Macromol. 2018;107:1428–37. 
37. Stärtzel P. Arginine as an excipient for protein freeze-drying: a mini review. J Pharm 
Sci. 2018;107:960–7. 
38. Hackl E, Darkwah J, Smith G, Ermolina I. Effect of arginine on the aggregation of 
protein in freeze-dried formulations containing sugars and polyol: 1-formulation 
development. AAPS PharmSciTech. 2018;19:896–911. 
39. Flores-Fernández GM, Solá RJ, Griebenow K. The relation between moisture-
induced aggregation and structural changes in lyophilized insulin. J Pharm Pharmacol. 
2009;61:1555–61. 
40. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug 
Discov. 2003;2:214–21. 
41. Smith G, Polygalov E, Arshad MS, Page T, Taylor J, Ermolina I. An impedance-
based process analytical technology for monitoring the lyophilisation process. Int J 
Pharm. 2013;449:72–83. 
42. Smith G, Arshad MS, Polygalov E, Ermolina I, Nazari K, Taylor J, et al. A new in-
line process analytical technology for freeze-drying. Pharm Tech. 2014;38:38–46. 
43. Arshad MS, Smith G, Polygalov E, Ermolina I. Through-vial impedance 
spectroscopy of critical events during the freezing stage of the lyophilization cycle: the 
example of the impact of sucrose on the crystallization of mannitol. Eur J Pharm 
Biopharm. 2014;87:598–605. 
44. Fasman DG. Practical handbook of biochemistry and molecular biology. Boston: 
CRC Press; 1992. 
45. Hackl EV, Darkwah J, Smith G, Ermolina I. Effect of acidic and basic pH on 
Thioflavin T absorbance and fluorescence. Eur Biophys J. 2015;44:249–61. 
46. Aragones JL, MacDowell LG, Vega C. Dielectric constant of ices and water: a lesson 
about water interactions. J Phys Chem A. 2011;115:5745–58. 
47. Michnik A. Thermal stability of bovine serum albumin DSC study. J Therm Anal 
Calorim. 2003;71:509–19. 
48. Auton M, Bolen DW. Additive transfer free energies of the peptide backbone unit 
that are independent of the model compound and the choice of concentration scale. 
Biochemistry. 2004;43:1329–42. 
49. Timasheff SN. Thermodynamic binding and site occupancy in the light of the 
Schellman exchange concept. Biophys Chem. 2002;101:99–111. 
50. Hulse WL, Forbes RT, Bonner MC, Getrost M. The characterization and comparison 
of spray-dried mannitol samples. Drug Dev Ind Pharm. 2009;35:712–8. 
51. Fronczek FR, Kamel HN, Slattery M. Three polymorphs (α, β, and δ) of D-mannitol 
at 100 K. Acta Crystallogr C. 2003;59:O567–70. 
52. Dierks TM, Korter TM. Origins of the relative stabilities of anhydrous and hydrated 
D-mannitol crystals. J Phys Chem A. 2016;120:6629–36. 
53. Larsen HML, Trnka H, Grohganz H. Formation of mannitol hemihydrate in freeze-
dried protein formulations—a design of experiment approach. Int J Pharm. 2014;460:45–
52. 
54. Jena S, Horn J, Suryanarayanan R, Friess W, Aksan A. Effects of excipient 
interactions on the state of the freeze-concentrate and protein stability. Pharm Res. 
2017;34:462–78. 
55. Jena S, Suryanarayanan R, Aksan A. Mutual influence of mannitol and trehalose on 
crystallization behavior in frozen solutions. Pharm Res. 2016;33:1413–25. 
56. Roe KD, Labuza TP. Glass transition and crystallization of amorphous trehalose-
sucrose mixtures. Int J Food Prop. 2005;8:559–74. 
57. Surana R, Pyne A, Suryanarayanan R. Effect of preparation method on physical 
properties of amorphous trehalose. Pharm Res. 2004;21:1167–76. 
58. Mattern M, Winter G, Kohnert U, Lee G. Formulation of proteins in vacuum-dried 
glasses. II. Process and storage stability in sugar-free amino acid systems. Pharm Dev 
Technol. 1999;4:199–208. 
59. Tian F, Sane S, Rytting JH. Calorimetric investigation of protein/amino acid 
interactions in the solid state. Int J Pharm. 2006;310:175–86. 
60. Wolkers WF, Oldenhof H, editors. Cryopreservation and freeze-drying protocols, 
methods in molecular biology, vol. 1257. New York: Springer Science+Business Media; 
2015. 
61. LeVine H 3rd. Quantification of beta-sheet amyloid fibril structures with thioflavin 
T. Methods Enzymol. 1999;309:274–84. 
62. Carpenter JF, Crowe JH. An infrared spectroscopic study of the interactions of 
carbohydrates with dried proteins. Biochemistry. 1989;28:3916–22. 
 
